Search research articles
Contact Us
Filters
Showing results (91-100 of 113) with videos related to
Page
of 12
Sort By:
Leukemia
|
December 26, 2001
Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphoma
M Ladetto, F Zallio, S Vallet, et al.
British Journal of Haematology
|
January 4, 2024
Prognostic impact of pretreatment cell-free DNA concentration in newly diagnosed peripheral T-cell lymphomas
E Fardella, G Zanirato, M Magni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 24, 2016
Myeloablative versus reduced intensity allogeneic stem cell transplantation for relapsed/refractory Hodgkin's lymphoma in recent years: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation
S Genadieva-Stavrik, A Boumendil, P Dreger, et al.
Leukemia
|
March 26, 2014
Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma
P Corradini, U Vitolo, A Rambaldi, et al.
Leukemia
|
May 6, 2016
Post-transplant cyclophosphamide-based haplo-identical transplantation as alternative to matched sibling or unrelated donor transplantation for non-Hodgkin lymphoma: a registry study by the European society for blood and marrow transplantation
S Dietrich, H Finel, C Martinez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 20, 2005
Effect of age and previous autologous transplantation on nonrelapse mortality and survival in patients treated with reduced-intensity conditioning and allografting for advanced hematologic malignancies
P Corradini, F Zallio, J Mariotti, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
July 13, 2020
Refractory and 17p-deleted chronic lymphocytic leukemia: improving survival with pathway inhibitors and allogeneic stem cell transplantation
L Farina, F Barretta, L Scarfò, et al.
Leukemia
|
January 12, 2019
Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma
A Dodero, A Guidetti, A Tucci, et al.
Leukemia
|
June 29, 2007
Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome
P Corradini, A Dodero, L Farina, et al.
Leukemia
|
August 26, 2006
Prolonged survival and low incidence of late toxic sequelae in advanced follicular lymphoma treated with a TBI-free autografting program: updated results of the multicenter consecutive GITMO trial
M Ladetto, S Vallet, F Benedetti, et al.
Page
of 12
Search research articles
Search
Showing results (91-100 of 113) with videos related to
Sort By:
Page
of 12
Leukemia
|
December 26, 2001
Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphoma
M Ladetto, F Zallio, S Vallet, et al.
British Journal of Haematology
|
January 4, 2024
Prognostic impact of pretreatment cell-free DNA concentration in newly diagnosed peripheral T-cell lymphomas
E Fardella, G Zanirato, M Magni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 24, 2016
Myeloablative versus reduced intensity allogeneic stem cell transplantation for relapsed/refractory Hodgkin's lymphoma in recent years: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation
S Genadieva-Stavrik, A Boumendil, P Dreger, et al.
Leukemia
|
March 26, 2014
Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma
P Corradini, U Vitolo, A Rambaldi, et al.
Leukemia
|
May 6, 2016
Post-transplant cyclophosphamide-based haplo-identical transplantation as alternative to matched sibling or unrelated donor transplantation for non-Hodgkin lymphoma: a registry study by the European society for blood and marrow transplantation
S Dietrich, H Finel, C Martinez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 20, 2005
Effect of age and previous autologous transplantation on nonrelapse mortality and survival in patients treated with reduced-intensity conditioning and allografting for advanced hematologic malignancies
P Corradini, F Zallio, J Mariotti, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
July 13, 2020
Refractory and 17p-deleted chronic lymphocytic leukemia: improving survival with pathway inhibitors and allogeneic stem cell transplantation
L Farina, F Barretta, L Scarfò, et al.
Leukemia
|
January 12, 2019
Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma
A Dodero, A Guidetti, A Tucci, et al.
Leukemia
|
June 29, 2007
Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome
P Corradini, A Dodero, L Farina, et al.
Leukemia
|
August 26, 2006
Prolonged survival and low incidence of late toxic sequelae in advanced follicular lymphoma treated with a TBI-free autografting program: updated results of the multicenter consecutive GITMO trial
M Ladetto, S Vallet, F Benedetti, et al.
Page
of 12